Al Hammadi Holding (4007) Fair Value & Analysis
Healthcare · SA · Market cap 4.2B SAR
Fair value as of: Jul 31, 2026
From 26 valuation models · updated today
Share price −4.0% over the past month.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- A fairly wide model range (13.37 SAR to 32.76 SAR) leaves room in how you read the outcome.
Price vs Fair Value (12 months)
12‑month range 23.49 SAR – 35.33 SAR · fair‑value band 13.37 SAR – 32.76 SAR · the 25.94 SAR price screens above the 23.87 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Al Hammadi Holding (4007) currently trades at 25.94 SAR, while our model-based Fair Value estimate is 23.87 SAR, implying the stock looks roughly 8.0% fairly valued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Al Hammadi Holding generated revenue of 1.3B SAR at a net margin of 17.9%. Revenue grew 5.7% year over year. It earns a return on equity of 11.2%. Net debt stands at 159M SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 13.37 SAR (bear case) to 32.76 SAR (bull case); at 25.94 SAR, the current price sits within that range. The share trades about 27% below its 52-week high and 12% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at -8%, 4007 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Al Hammadi Holding Company, a healthcare group, provides healthcare services in the Kingdom of Saudi Arabia. The company operates through Medical Services and Pharmaceuticals Products segments.
Full company description
Al Hammadi Holding Company, a healthcare group, provides healthcare services in the Kingdom of Saudi Arabia. The company operates through Medical Services and Pharmaceuticals Products segments. The company offers inpatient and outpatient hospital services, including accommodation, medical professional services, equipment, radiology, laboratory, and bundled healthcare offerings; and provides medical services. The company was formerly known as Al Hammadi Company For Development and Investment and changed its name to Al Hammadi Holding Company in August 2022. Al Hammadi Holding Company was founded in 1985 and is based in Riyadh, the Kingdom of Saudi Arabia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Al Hammadi Holding reported revenue of 1.2B SAR in FY2025 versus 952M SAR in FY2021, a compound +6.7%/yr. Reported net income was 242M SAR in FY2025, compounding +28.0%/yr from FY2021.
Is 4007 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$97.60 | R$115.75 | +19% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.76 SGD | 1.28 SGD | -54% |
| Tenet Healthcare Corporation THC | $162.06 | $282.55 | +74% |
| Rede D'Or São Luiz S.A RDOR3 | R$33.83 | R$46.94 | +39% |
| DaVita Inc DVAI34 | R$1,030 | R$1,096 | +7% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,489 | ₹2,128 | -75% |
| Fresenius Medical Care AG FMSC34 | R$112.00 | R$164.60 | +47% |
| Aier Eye Hospital Group 300015 | ¥8.25 | ¥6.73 | -18% |
Compare Al Hammadi Holding with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Al Hammadi Holding (4007) overvalued or undervalued?
What is the fair value of 4007?
What is the quality score of 4007?
What is the revenue of Al Hammadi Holding (4007)?
What is the net profit margin of 4007?
Does Al Hammadi Holding pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Al Hammadi Holding and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.